Clinical Trials Logo

Stage IA Breast Cancer clinical trials

View clinical trials related to Stage IA Breast Cancer.

Filter by:

NCT ID: NCT01712815 Terminated - Clinical trials for HER2-positive Breast Cancer

PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer

Start date: November 22, 2013
Phase: N/A
Study type: Interventional

This phase I trial studies the side effects of positron emission tomography (PET)/computed tomography (CT) in evaluating response to chemotherapy in patients with breast cancer. Comparing results of diagnostic procedures done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment.

NCT ID: NCT01672684 Completed - Depression Clinical Trials

Phase I: At-Home Support for Rural Women Using Group Video Calling

Start date: October 2012
Phase: Phase 1
Study type: Interventional

This randomized phase I trial studies at-home group video calling sessions in quality of life in rural patients with breast cancer. At-home group video calling support sessions may improve the well-being and quality of life of women who have breast cancer

NCT ID: NCT01570998 Recruiting - Clinical trials for Stage IA Breast Cancer

Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery

Start date: May 18, 2012
Phase: N/A
Study type: Interventional

This phase IV trial studies the side effects of intraoperative radiation therapy and how well it works in treating patients with breast cancer undergoing breast-conserving surgery. Delivering radiation one time to the area where the tumor was removed while the patient is still in the operating room may kill any residual tumor cells and may be as effective as standard radiation therapy in patients with early stage breast cancer.

NCT ID: NCT01522820 Completed - Glioblastoma Clinical Trials

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Start date: March 2012
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best schedule of vaccine therapy with or without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid tumors. Biological therapies, such as sirolimus, may stimulate the immune system in different ways and stop tumor cells from growing. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells that express NY-ESO-1. Infusing the vaccine directly into a lymph node may cause a stronger immune response and kill more tumor cells. It is not yet known whether vaccine therapy works better when given with or without sirolimus in treating solid tumors.

NCT ID: NCT01483196 Completed - Clinical trials for Stage IIIA Breast Cancer

Vascular and Cognitive Assessments in Patients With Breast Cancer Undergoing Chemotherapy After Surgery

Start date: January 2012
Phase: N/A
Study type: Interventional

This clinical trial studies vascular and cognitive assessments in patients with breast cancer undergoing chemotherapy after surgery. Learning about vascular and cognitive function may help plan treatment and improve the quality of life of breast cancer patients. Transcranial Doppler ultrasound (TCD) may help study the side effects of chemotherapy in breast cancer patients and allow doctors to plan better treatment

NCT ID: NCT01478477 Completed - Clinical trials for Stage IIIA Breast Cancer

Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole

Start date: October 4, 2011
Phase: N/A
Study type: Interventional

This randomized pilot trial studies omega-3 fatty acid in preventing joint symptoms in patients with stage I-III breast cancer receiving anastrozole, exemestane, or letrozole. Omega-3 fatty acid supplement may lessen or prevent joint stiffness or pain in patients receiving hormone therapy for breast cancer.

NCT ID: NCT01409811 Terminated - Clinical trials for Stage IB Breast Cancer

Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid

Start date: September 14, 2012
Phase: N/A
Study type: Interventional

This pilot clinical trial studies biomarkers in tissue samples from patients with newly diagnosed breast cancer treated with zoledronic acid (ZA). Studying samples of tumor tissue in the laboratory from patients receiving ZA may help doctors learn more about the effects of ZA on cells. It may also help doctors understand how well patients respond to treatment.

NCT ID: NCT01391689 Completed - Clinical trials for Stage IIIA Breast Cancer

Diindolylmethane in Treating Patients With Breast Cancer

Start date: February 2011
Phase: N/A
Study type: Interventional

This phase II/III trial studies how well diindolylmethane (DIM) works and compares it to placebo in treating patients with breast cancer. DIM may slow the growth of tumor cells and be an effective treatment for breast cancer.

NCT ID: NCT01372579 Active, not recruiting - Clinical trials for Stage IIIA Breast Cancer

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

Start date: August 2011
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well giving eribulin mesylate and carboplatin together before surgery works in treating patients with stage I-III triple-negative breast cancer. Drugs used in chemotherapy, such as eribulin mesylate and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

NCT ID: NCT01319539 Terminated - Clinical trials for Stage IIIA Breast Cancer

MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Start date: April 2011
Phase: Phase 2
Study type: Interventional

This phase II trial is studies how well Akt inhibitor MK2206 works in treating patients with stage I-III breast cancer that can be removed by surgery. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.